A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Participants with \>=40 to less than or equal to (\<=) 80 years of age.
An eosinophilic phenotype with elevated BEC.
Moderate to very severe COPD with frequent exacerbations.
Participants with elevated COPD assessment test (CAT) score.
Current or former cigarette smokers.
On triple (Inhaled corticosteroid \[ICS\]+ Long-acting muscarinic antagonist \[LAMA\]+ Long-acting beta-agonist \[LABA\]) or dual inhaled COPD therapy, if ICS is considered not appropriate.
You may not be if
Current or prior physician diagnosis of asthma
Other clinically significant lung disease.
Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.
Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure.
Continuous oxygen therapy (more than 16 hours/ day).
Cor pulmonale resulting in right heart failure and severe pulmonary hypertension.
A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix).
Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia.
New York Heart Association class III or IV heart failure.
Other significant medical conditions that could impact participants' safety or study outcomes.
Clareo Health | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
